Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

(Gedeon Richter), and the associated cash capital increase at the beginning of 2024, allowed Formycon to raise €82.84 million for the further development of its existing biosimilar pipeline. In return ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

SHANGHAI, China & JERSEY CITY, NJ, USA I March 28, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the ...

as the company expands its biosimilar pipeline. Amneal’s growth strategy heavily relies on new product launches and pipeline development. The recent launch of CREXONT has been particularly ...

We have the strongest in-house developed product pipeline in the biosimilar industry based on official available data. Ten products are in advanced development and additionally 18 molecules have ...